STXS Stock - Stereotaxis, Inc.
Unlock GoAI Insights for STXS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $26.92M | $26.77M | $28.15M | $35.02M | $26.63M |
| Gross Profit | $14.59M | $14.86M | $18.47M | $23.23M | $18.97M |
| Gross Margin | 54.2% | 55.5% | 65.6% | 66.3% | 71.2% |
| Operating Income | $-24,739,000 | $-21,839,000 | $-18,776,000 | $-12,888,000 | $-6,713,815 |
| Net Income | $-24,045,000 | $-20,713,000 | $-18,292,000 | $-10,716,000 | $-6,646,459 |
| Net Margin | -89.3% | -77.4% | -65.0% | -30.6% | -25.0% |
| EPS | $-0.30 | $-0.27 | $-0.26 | $-0.16 | $-0.11 |
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 16th 2025 | Citizens JMP | Initiation | Mkt Outperform | $4 |
| January 10th 2024 | ROTH MKM | Initiation | Buy | $5 |
| July 12th 2022 | Aegis Capital | Initiation | Buy | $6 |
| June 23rd 2022 | B. Riley Securities | Initiation | Buy | $6 |
Earnings History & Surprises
STXSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.06 | — | — | — |
Q4 2025 | Nov 11, 2025 | $-0.06 | $-0.03 | +50.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.07 | $-0.05 | +28.6% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.07 | $-0.07 | 0.0% | = MET |
Q1 2025 | Mar 3, 2025 | $-0.06 | $-0.09 | -50.0% | ✗ MISS |
Q4 2024 | Nov 11, 2024 | $-0.05 | $-0.08 | -60.0% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.05 | $-0.07 | -33.3% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q1 2024 | Mar 4, 2024 | $-0.07 | $-0.07 | 0.0% | = MET |
Q4 2023 | Nov 9, 2023 | $-0.05 | $-0.07 | -40.0% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.05 | $-0.07 | -40.0% | ✗ MISS |
Q1 2023 | Mar 3, 2023 | $-0.06 | $-0.06 | 0.0% | = MET |
Q4 2022 | Nov 10, 2022 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.06 | $-0.06 | 0.0% | = MET |
Q1 2022 | Mar 3, 2022 | $-0.05 | $-0.05 | -3.2% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-0.05 | $-0.07 | -50.0% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.01 | $-0.02 | -66.7% | ✗ MISS |
Latest News
Citizens Initiates Coverage On Stereotaxis with Market Outperform Rating, Announces Price Target of $4
📈 PositiveRoth Capital Reiterates Buy on Stereotaxis, Maintains $4 Price Target
📈 PositiveStereotaxis shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeStereotaxis shares drop after Q3 loss widens, GenesisX limited launch underway
📉 NegativeStereotaxis shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeStereotaxis Q3 EPS $(0.07) Misses $(0.06) Estimate, Sales $7.464M Miss $8.375M Estimate
📉 NegativeStereotaxis Granted FDA 510(k) For Its GenesisX RMN System With Navigant Workstation And Cardiodrive As Substantially Equivalent
📈 PositiveRoth Capital Reinstates Buy on Stereotaxis, Announces $4 Price Target
📈 PositiveStereotaxis Receives CE Mark, Seeks FDA Approval for Synchrony Surgical Robotics System
📈 PositiveStereotaxis Enters Collaboration Agreement To Advance Robotic Pulsed Field Ablation For Cardiac Arrhythmias
📈 PositiveStereotaxis' Genesis Robotic Magnetic Navigation System Used In First Procedures By Physicians At Erasmus University MC In Netherlands
📈 PositiveStereotaxis announces $12.5 million offering; shares slip over 7%
📉 NegativeFrequently Asked Questions about STXS
What is STXS's current stock price?
What is the analyst price target for STXS?
What sector is Stereotaxis, Inc. in?
What is STXS's market cap?
Does STXS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to STXS for comparison